Ligand Pharmaceuticals Incorporated (LGND) Business Profile

What it does

Ligand Pharmaceuticals is a biopharmaceutical royalty company. Rather than relying primarily on selling medicines itself, it invests in rights to receive payments tied to medicines developed and sold by other companies. Its customers and counterparties include drug developers, pharmaceutical companies, inventors and institutions that own royalty rights. Todd Davis is its chief executive officer.

Ligand buys existing royalty rights, finances drug development in exchange for a share of future sales, and acquires companies or assets that contain royalty rights. Its partners generally handle the clinical development, regulatory work, manufacturing and commercial sales of the underlying products. Ligand evaluates investments and manages the resulting portfolio.

The company also licenses technologies used by partners. Captisol is a chemically modified ingredient designed to improve a drug’s solubility and stability. NITRICIL uses nitric oxide’s antimicrobial and immune-modulating properties to support the development of treatments. Ligand earns royalties when products using its technologies are sold and also sells Captisol material.

Its portfolio spans commercial medicines and products still in development. The latter may not generate sales or royalties unless they reach the market. In July 2026, Ligand completed its acquisition of XOMA Royalty, adding commercial assets and pipeline programs. Ligand had 47 employees in FY2025.

How it makes money

Ligand’s principal revenue source is royalties on sales of medicines commercialized by its partners. Royalty rates are set by individual agreements and can be fixed, tiered or linked to profit. The company also receives license fees and milestone payments when contractual events occur, and sells Captisol material to partners using the technology in their products.

For example, Ligand supplies Captisol to Amgen for Kyprolis and is entitled to a 1.5% to 3.0% royalty on its annual net sales. Its agreement for Filspari provides a 9% royalty on worldwide sales and potential milestones. Its Ohtuvayre royalty is 3% of global net sales. Ligand’s teriparatide arrangement instead provides tiered gross profit sharing of between 25% and 40% of quarterly profit.

Royalty payments can recur as long as a product is sold and the contractual obligation remains in force. Their amounts depend on partner sales and agreement terms. Some rates increase at higher sales tiers, while milestone and Captisol revenue depend on the timing of events and customer orders.

For FY2025, total revenue and income were $268.1 million; for Q3 2026, total core revenue was $78.7 million.

Royalty receipts and accounting income are not always the same. Financial royalty assets represent rights to future payments without ownership of the underlying intellectual property or commercialization rights. Ligand recognizes income on these assets using expected cash flows over their lives. Following XOMA, the company said its financial royalty asset balance rose from approximately $200 million to $800 million. Ligand also estimates royalty income when partners have not yet reported sales and adjusts differences in the following quarter.

Customers and how it sells

Ligand works with pharmaceutical partners that develop, manufacture and sell products, as well as owners of royalty rights seeking to monetize them. It generally receives payments through contracts with those counterparties rather than selling the underlying medicines directly to patients.

Amgen licenses Captisol and purchases material for Kyprolis. Travere holds worldwide rights to Filspari, while Ligand receives royalties on its sales. Merck is a partner on products including Ohtuvayre, Capvaxive and Vaxneuvance. Recordati pays Ligand royalties on Qarziba.

In FY2025, Partner A represented 22.0% of revenue, Partner B 17.0%, and Partner C 12.0%. Those labels do not identify the partners by name.

Ligand’s agreements and partner products reach beyond the United States. Qarziba is commercially available in more than 35 countries outside of the U.S.; Filspari has been approved in Europe, and Chugai has rights to develop and commercialize it in Japan and other Asian countries. Ligand’s Pneumosil partner, Serum Institute of India, commercializes the vaccine in India. Ligand also maintains active Captisol regulatory files in Japan, China and Canada that licensees can reference when developing Captisol-enabled drugs.

Suppliers and costs

Ligand relies on its partners’ manufacturing, sales, marketing and research infrastructure for the medicines that generate royalties. Its own Captisol business supplies material to partners. Captisol is available as a powder and as a manufactured aqueous concentrate.

Hovione supplies Captisol under a purchase agreement, and Ligand identifies its Captisol supply as dependent on a sole supplier. As of December 31, 2025, the total purchase obligation under the supply agreement was $25.4 million, of which $12.6 million was expected to be paid within a year.

Ligand’s operating costs include Captisol costs, research and development, general and administrative expenses, and amortization of acquired intangible assets. Some development-financing arrangements are recorded as research and development expense: in 2025, these included a $44.3 million arrangement related to Castle Creek’s D-Fi royalty rights and a $17.8 million arrangement related to Orchestra.

In Q3 2026, general and administrative expense included $35 million of one-time XOMA transaction and integration costs. Ligand expected approximately $50 million of core cash operating expenses for 2026, including XOMA.

Competitive position

Ligand competes for opportunities to purchase royalty rights and finance biopharmaceutical products. The company says commercial-stage royalty investments are highly competitive and that multiple parties usually bid on an asset or financing transaction. It does not name individual competitors in its competition disclosures.

At the product level, medicines sold by Ligand’s partners can compete with existing therapies or products in development. Captisol can also face competition from suppliers of similar ingredients and other technologies designed to improve drug solubility or stability.

Ligand’s competitive position depends partly on its ability to obtain patent protection or develop proprietary products and processes. Its Captisol patent portfolio has a latest expiration date in 2033; other applications covering manufacturing methods, if issued, would extend the expiration date to 2041. Its partners’ patents and regulatory protections can also affect the products underlying royalty contracts.

Our reading: Captisol’s patents provide a product-specific source of protection, but their duration is finite and alternative technologies can compete. Our reading: Ligand’s relationships and access to non-public diligence materials can help it find and evaluate transactions, although multiple bidders compete for commercial assets. Our reading: Its ability to acquire and restructure companies may help it pursue more complex transactions, but the outcomes still depend on the acquired rights and partner products.

Growth opportunities

Ligand seeks growth by investing capital in royalty rights and licensing its technologies. It buys existing royalties, finances development-stage programs, acquires companies or assets with embedded rights, and invests in intellectual-property platforms. It generally seeks products within a few years of regulatory approval and commercialization, while also considering earlier-stage opportunities.

The July 2026 XOMA acquisition added three key commercial assets and more than 100 pipeline programs. Ligand said the acquired commercial assets included Vabysmo, Ojemda and Miplyffa. It also made investments in AvenCell, a cell-therapy platform, and Ryjunea, a pediatric myopia product.

Growth can also come from partner product sales and additional approved uses. Ligand identified the launch of Filspari in focal segmental glomerulosclerosis as a primary driver of Q3 2026 royalty growth. Royalty revenue was $70.3 million in that quarter, an increase of 51% over the prior year.

Ligand expects royalty revenue of $225 million to $250 million for 2026. It expects revenue to be weighted more heavily toward the fourth quarter, partly because that period will include a full quarter of XOMA royalties and because some royalty rates increase as annual sales rise.

Further potential royalties depend on clinical and regulatory outcomes. Palvella’s QTORIN rapamycin application received priority review, with a February 28, 2027 target date. Ligand would earn a tiered 8% to 9.8% royalty if it is approved.

Structural risks

• Partner dependence: Future revenue from partner products is not guaranteed. Partners can change strategy or focus, become insolvent, encounter development or regulatory hurdles, or fail to achieve market acceptance for their products.

• Clinical and regulatory outcomes: Product candidates can fail clinical studies or face delayed, limited or denied approvals. Ligand’s development-stage royalty rights and potential milestones depend on the progress of underlying programs.

• Competition and intellectual property: Partner medicines can face competing products, and third-party intellectual property can prevent development. Ligand’s and its partners’ patents may not prevent competition and can be subject to disputes over their validity or scope.

• Supply and manufacturing: An interruption at Ligand’s sole Captisol supplier could affect its ability to source the material. Manufacturing of products that generate royalties is typically complex and subject to regulation.

• Concentration and estimation: In FY2025, Partner A, Partner B and Partner C represented 22.0%, 17.0% and 12.0% of revenue, respectively. Ligand also estimates some quarterly royalties before partners report sales; actual results can differ.

• Transaction and investment exposure: Ligand’s royalty asset values depend on assumptions about future cash flows. Acquisitions can create integration difficulties, and the company retains exposure to Pelthos through equity ownership and other investments.

Bottom line

Our reading

Ligand is a royalty investor and technology licensor whose revenue depends on medicines developed and sold by partners, rather than a conventional drug manufacturer (item1). Its expanded portfolio provides exposure to multiple products, but results still depend on partner execution, clinical outcomes and the accuracy of royalty cash-flow estimates (item1a; item7; call_prepared). XOMA increased the portfolio and financial royalty assets, while adding transaction costs and changing the scale of the business (call_prepared).